Frelii Appoints Two New Members to its Scientific Advisory Board

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) today announced
that it has appointed two renowned physicians, Anthony R. Torres, M.D.
and Susan H. Morelli M.D., to its Scientific Advisory Board.

“The expertise, experience and guidance of Dr. Morelli and Dr. Torres
will help Frelii accelerate and improve our pilot clinical trials, which
will drive an increase in the speed of learning of our algorithms and AI
platform,” said Ian Jenkins, CEO of Frelii. “We are thrilled to welcome
these two incredible minds to the team as we address the challenges and
opportunities of delivering practical and accurate whole-genome
sequencing solutions to the market. Having Dr. Morelli and Dr. Torres on
our Advisory Board is a significant validation of Frelii, the company’s
technology and its direction in the industry.”

Dr. Torres received his M.D. degree at the University of Utah and
completed his postdoctoral training as a Research Associate at
the National Institutes of Health and as a resident at Yale University.
He has been published in dozens of peer-reviewed journals for his work
in protein chemistry, molecular biology, the genetics of autism and
more. Dr. Torres has had an illustrious career not only in university
research, but also in the biotechnology field. He also obtained seven
patents for novel inventions in numerous areas.

Dr. Morelli is a neonatologist at Utah Valley Hospital and is affiliated
with multiple hospitals in the area. She received her bachelor’s degree
in mathematics from Harvard University and her medical degree from
University of Connecticut School of Medicine. She is has been published
in several journal articles and has been in practice for nearly 25
years. She has held the position of instructor at the Department of
Pediatrics, Division of Medical Genetics at the University of Utah and
she is board certified by the American Board of Pediatrics and the
American Board of Medical Genetics.

These two individuals are joining the Frelii Inc. Scientific Advisory
Board, which includes Dr. Shayne Morris, a molecular biologist and Dr.
Hans Jenkins, the Chief Medical Officer of Frelii.

About Frelii Inc.

Frelii Inc. is a medical technology company that uses gene sequencing
and artificial intelligence to determine risk and lifestyle
modifications. Its technology analyzes the most comprehensive markers
(60,000,000+) on the market to date. Frelii’s technology generates
accurate and profoundly valuable insight into DNA. It opens
opportunities never before realized in health care, precision medicine,
insurance, corporate wellness as well as personal health and risk
identification. For more information, please visit
Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage
and developing U.S. and international companies. Companies are current
in their reporting and undergo an annual verification and management
certification process. Investors can find Real-Time quotes and market
information for the company on

Follow Frelii online at:

Frelii Facebook Page
Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
LinkedIn Page

Safe Harbor Statement:

This release contains certain “forward-looking statements” relating to
the business of the Company. All statements, other than statements of
historical fact included herein are “forward-looking statements”
including statements regarding: the continued growth of the e-commerce
segment and the ability of the Company to continue its expansion into
that segment; the ability of the Company to attract customers and
partners and generate revenues; the ability of the Company to
successfully execute its business plan; the business strategy, plans,
and objectives of the Company; and any other statements of
non-historical information. These forward-looking statements are often
identified by the use of forward-looking terminology such as “believes,”
“expects” or similar expressions and involve known and unknown risks and
uncertainties. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they do
involve assumptions, risks, and uncertainties, and these expectations
may prove to be incorrect. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date of
this news release. The Company’s actual results could differ materially
from those anticipated in these forward-looking statements as a result
of a variety of factors, including those discussed in the Company’s
periodic reports that are filed with the Securities and Exchange
Commission and available on its website (
All forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the Company
does not assume any duty to update these forward-looking statements.


Media Contact:
Tim Rush

error: Content is protected !!